Stock BGNE BEIGENE, LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News BeiGene, Ltd.

Equities

BGNE

US07725L1026

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-15 pm EDT 		5-day change 1st Jan Change
138.4 USD -2.05% Intraday chart for BeiGene, Ltd. -7.58% -23.26%
Apr. 11 Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech MT
Apr. 11 Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech
MT
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech
MT
BeiGene Opens New Factory in Guangzhou for Antibody-Drug Conjugates
MT
Beigene Shrinks Loss by 56% in 2023
MT
Bernstein Adjusts BeiGene's Price Target to $161 From $196, Maintains Market Perform Rating
MT
Tech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Slightly Lower in Friday Trading
MT
BeiGene, Ltd. Announces Executive Changes
CI
BeiGene Receives FDA Approval for TEVIMBRA for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma after Prior Chemotherapy
AQ
Beigene's Esophageal Cancer Drug Gets US FDA Nod
MT
Beigene Insider Sold Shares Worth $8,368,017, According to a Recent SEC Filing
MT
BeiGene Says FDA Approves Tevimbra to Treat Some Esophageal Cancer Patients
DJ
BeiGene Gets FDA Approval for Esophageal Cancer Treatment
MT
BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
BU
BeiGene, Ltd. Receives FDA Approval for TEVIMBRA for Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
CI
US FDA approves BeiGene's esophageal cancer therapy
RE
First Doses of BRUKINSA provided to Patients with Chronic Lymphocytic Leukemia in Low and Middle-Income Countries under Collaboration of the Max Foundation, BeiGene, and the BeiGene Foundation
AQ
BeiGene Sells Over 1 Million Underlying Shares Under Purchase Plan
MT
Asian Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading
MT
BeiGene, Max Foundation Providing Brukinsa to Leukemia Patients in Armenia, Nepal as Part of 3-Year Partnership
MT
BeiGene Shares Rise on First Dosing of Brukinsa
DJ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BGNE Stock
  4. News BeiGene, Ltd.